Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q2 2023 Earnings Presentation
7 slides from Hls Therapeutics's earnings presentation, Aug 10, 2023
Slide 1: Q2 2023 Conference Call
Q2 2023 Conference Call Craig Millian, CEO Poised for High Growth Tim Hendrickson, CFO TSX - HLS
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Leadership / Structural Changes
Leadership / Structural Changes Executive Changes Board Changes John Welborn Craig Millian appointed Chair appointed CEO & Director Christian Roy, Craig Millian and Brian Walsh John Hanna joined the board appointed SVP & Head of Commercial Board size reduced from ten to eight members Shifted return
Slide 4: Vascepa: Continued Prescription Growth
Vascepa: Continued Prescription Growth Weekly script data since launch 2000 1800 1600 91% increase in total 1400 prescriptions* Prescriptions 1200 (*Q2 2023 compared to Q2 2022) 1000 800 600 96% increase in prescribers* 400 139% increase in 200 consistent prescribers* (*Q2 2023 compared to Q2 2022)
Slide 5: Vascepa Outlook
Vascepa Outlook 2023 Vascepa revenue target 1 Adapt go-to-market model C$18-20M Improve reimbursement 2 dynamics Vascepa positive direct contribution to Adjusted EBITDA in 2H 2024 3 Generate balanced payer mix Prioritizing 3 areas to generate sustained growth and brand profitability Provided as part
Slide 6: Adjusted EBITDA Contribution (year-to-date ended June 30, 2023)
Adjusted EBITDA Contribution (for the year-to-date period ended June 30, 2023) Objective: Clozaril’s direct contribution to Vascepa begins to generate Adjusted EBITDA: positive direct contribution to Adjusted EBITDA $14.4M in the 2H 2024 Vascepa’s direct contribution (loss) to Adjusted EBITDA: ($4.7
Slide 7: Q2 2023 Conference Call
Q2 2023 Conference Call Craig Millian, CEO Poised for High Growth Tim Hendrickson, CFO TSX - HLS